Placebo News and Research

RSS

FDA approves INVEGA treatment for schizophrenia

The U.S. Food and Drug Administration (FDA) has approved INVEGA (paliperidone) Extended-Release Tablets, a new once-daily, atypical antipsychotic, for the long-term maintenance treatment of schizophrenia.

30 Apr 2007

Drug for toenail fungus also blocks angiogenesis

Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers.

30 Apr 2007

Heavy use of cannabis triggers psychotic illnesses

Scientists in the UK say the heavy consumption of the drug cannabis may trigger psychotic illnesses such as schizophrenia.

30 Apr 2007

Tarceva extends life of patients with pancreatic cancer

New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.

27 Apr 2007

Sangamo BioSciences starts phase 2 trial of therapy diabetic neuropathy

Sangamo BioSciences has announced that the company has initiated a repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN).

27 Apr 2007

Taking low dose aspirin does not protect older women against cognitive decline

Identifying ways to prevent dementia is a public health priority. Evidence suggests that aspirin and other anti-inflammatory drugs may protect against dementia, but data from randomised studies to date have been inconclusive.

27 Apr 2007

No evidence to support the use of Dan Shen for ischemic stroke

The herbal medicine Dan Shen, a standard treatment for ischemic stroke in China, lacks strong scientific evidence to support such use, according a new review of studies.

27 Apr 2007

Drugs that adjust dopamine levels in the brain greatly affect how people react to success and failure

In a first-of-its-kind study on humans, researchers measured how dopamine-related drugs affect the striatum, a part of the brain that is stimulated by rewards.

27 Apr 2007

Naproxen and celecoxib do not prevent Alzheimer's disease

Over-the-counter pain medication naproxen and prescription pain reliever celecoxib do not prevent Alzheimer's disease, according to a study published April 25, 2007, in the online edition of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2007

ADHD study to look at effects of different stimulant medications and dosages on sleep and mood

Researchers at the University of Illinois at Chicago are comparing two common stimulant drugs with a placebo to evaluate their effect on sleep and behavior in children with attention deficit hyperactivity disorder.

25 Apr 2007

Lisinopril could help stroke victims

A University of Leicester study could help to provide a new lease of life for patients who have suffered a stroke.

25 Apr 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Succimer therapy improves balance and movement in lead-exposed children

University of Cincinnati (UC) environmental health researchers say a therapy commonly used to remove dangerously high levels of lead from the body may also improve muscle functions associated with postural balance and movement in lead-exposed children.

25 Apr 2007

Time for FDA to set the record straight on common painkillers

The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe, says Curt Furberg, M.D., Ph.D., from Wake Forest University School of Medicine.

25 Apr 2007

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

25 Apr 2007

Professor Marc Feldmann wins top lifetime achievement award

The academic who developed a treatment for autoimmune diseases that has helped millions of patients around the world last night received a prestigious lifetime achievement award at this year's European Inventor of the Year awards.

24 Apr 2007

BioMS Medical announces lead investigator in phase III multiple sclerosis trial

BioMS Medical Corp has announced Dr. Clyde E. Markowitz as the lead investigator in the United States for the Company's pivotal phase III clinical trial of its lead drug, MBP8298, for the treatment of secondary progressive multiple sclerosis.

24 Apr 2007

Benefits of antidepressants for children far outweigh the risks

Researchers in the United States maintain that a review of research shows that the benefits of antidepressants for children and teens during the first few months of treatment far outweigh the risk of suicide.

22 Apr 2007

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007